Verona Pharma has clinched a $219 million deal to market its “first-in-class” drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD), in China.
Read More
Verona Pharma, which has its US headquarters in Raleigh, has lined up $30 million in financing from Silicon Valley Bank. We’ve got the details.
Read More
A British clinical-stage biotech firm with U.S. headquarters in Raleigh is exploring the option of repurposing its leading drug candidate to treat COVID-19 patients. Here’s what’s happening.
Read More
